Skip to main content
Log in

S3-Leitlinie Mammakarzinom: das lokoregionäre Rezidiv

S3 guidelines on breast cancer: locoregional recurrence

  • Leitthema
  • Published:
Der Gynäkologe Aims and scope

Zusammenfassung

Die Behandlung des lokoregionär rezidivierten Mammakarzinoms ist eine interdisziplinäre Herausforderung. Neben operativen Maßnahmen, die in der Regel eine vollständige Resektion zum Ziel haben, sind Strahlentherapie und die Systemtherapie tragende Säulen in der Behandlung. In der neuen S3-Leitlinie wird das Thema in einem eigenen Kapitel behandelt. Als Neuerung im Vergleich zu den vorangegangenen Leitlinien wird betont, dass unter gewissen Voraussetzungen eine erneute brusterhaltende Operation (Re-BEO) möglich ist. Da je nach Tumorbiologie, Tumorstadium und Vorgeschichte ganz unterschiedliche Therapiekonzepte möglich sind, werden individuelle Risikobewertung und Aufklärung in der Leitlinie explizit hervorgehoben.

Abstract

Treatment of locoregionally relapsed breast cancer is an interdisciplinary challenge. In addition to surgical procedures, which usually aim for a complete resection, radiotherapy and systemic therapy are essential pillars of treatment. The topic is dealt within a separate chapter in the new German S3 guidelines. Compared to previous guidelines, it is emphasized that under certain conditions breast-conserving can be reconsidered. Depending on tumor biology, tumor stage and medical history, various therapy concepts are possible. This is why individual risk assessment and patient information are highlighted in the guidelines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, Cannady RS, Pratt-Chapman ML, Edge SB, Jacobs LA, Hurria A, Marks LB, LaMonte SJ, Warner E, Lyman GH, Ganz PA (2016) American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol 34(6):611–635

    Article  PubMed  CAS  Google Scholar 

  2. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28(10):1684–1691

    Article  PubMed  Google Scholar 

  3. Metzger-Filho O, Sun Z, Viale G, Price KN, Crivellari D, Snyder RD, Gelber RD, Castiglione-Gertsch M, Coates AS, Goldhirsch A, Cardoso F (2013) Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol 31(25):3083–3090

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Moossdorff M, van Roozendaal LM, Strobbe LJ, Aebi S, Cameron DA, Dixon JM, Giuliano AE, Haffty BG, Hickey BE, Hudis CA, Klimberg VS, Koczwara B, Kuhn T, Lippman ME, Lucci A, Piccart M, Smith BD, Tjan-Heijnen VC, van de Velde CJ, Van Zee KJ, Vermorken JB, Viale G, Voogd AC, Wapnir IL, White JR, Smidt ML (2014) Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research. J Natl Cancer Inst 106(12):dju288

    Article  PubMed  PubMed Central  Google Scholar 

  5. Moy L, Newell MS, Mahoney MC, Bailey L, Barke LD, Carkaci S, D’Orsi C, Goyal S, Haffty BG, Harvey JA, Hayes MK, Jokich PM, Lee SJ, Mainiero MB, Mankoff DA, Patel SB, Yepes MM (2016) ACR appropriateness criteria stage I breast cancer: initial workup and surveillance for local recurrence and distant metastases in asymptomatic women. J Am Coll Radiol 13(11S):e43–e52

    Article  PubMed  Google Scholar 

  6. Witteveen A, Kwast AB, Sonke GS, IJzerman MJ, Siesling S (2015) Survival after locoregional recurrence or second primary breast cancer: impact of the disease-free interval. PLoS ONE 10(4):e120832

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Houssami N, Ciatto S, Martinelli F, Bonardi R, Duffy SW (2009) Early detection of second breast cancers improves prognosis in breast cancer survivors. Ann Oncol 20(9):1505–1510

    Article  PubMed  CAS  Google Scholar 

  8. Rapiti E, Verkooijen HM, Vlastos G, Fioretta G, Neyroud-Caspar I, Sappino AP, Chappuis PO, Bouchardy C (2006) Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol 24(18):2743–2749

    Article  PubMed  Google Scholar 

  9. Jobsen JJ, van der Palen J, Meerwaldt JH (2001) The impact of age on local control in women with pT1 breast cancer treated with conservative surgery and radiation therapy. Eur J Cancer 37(15):1820–1827

    Article  PubMed  CAS  Google Scholar 

  10. Alpert TE, Kuerer HM, Arthur DW, Lannin DR, Haffty BG (2005) Ipsilateral breast tumor recurrence after breast conservation therapy: outcomes of salvage mastectomy vs. salvage breast-conserving surgery and prognostic factors for salvage breast preservation. Int J Radiat Oncol Biol Phys 63(3):845–851

    Article  PubMed  Google Scholar 

  11. Deutsch M (2002) Repeat high-dose external beam irradiation for in-breast tumor recurrence after previous lumpectomy and whole breast irradiation. Int J Radiat Oncol Biol Phys 53(3):687–691

    Article  PubMed  Google Scholar 

  12. Andersson Y, de Boniface J, Jonsson PE, Ingvar C, Liljegren G, Bergkvist L, Frisell J, Swedish Breast Cancer G, Swedish Society of Breast S (2012) Axillary recurrence rate 5 years after negative sentinel node biopsy for breast cancer. Br J Surg 99(2):226–231

    Article  PubMed  CAS  Google Scholar 

  13. Haffty BG, Fischer D, Beinfield M, McKhann C (1991) Prognosis following local recurrence in the conservatively treated breast cancer patient. Int J Radiat Oncol Biol Phys 21(2):293–298

    Article  PubMed  CAS  Google Scholar 

  14. Waeber M, Castiglione-Gertsch M, Dietrich D, Thurlimann B, Goldhirsch A, Brunner KW, Borner MM, Swiss Group for Clinical Cancer R (2003) Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. Ann Oncol 14(8):1215–1221

    Article  PubMed  CAS  Google Scholar 

  15. Aebi S, Gelber S, Anderson SJ, Lang I, Robidoux A, Martin M, Nortier JW, Paterson AH, Rimawi MF, Canada JM, Thurlimann B, Murray E, Mamounas EP, Geyer CE Jr., Price KN, Coates AS, Gelber RD, Rastogi P, Wolmark N, Wapnir IL, Investigators C (2014) Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncol 15(2):156–163

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sara Y. Brucker.

Ethics declarations

Interessenkonflikt

S.Y. Brucker, A.D. Hartkopf und W. Janni geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Redaktion

A. Wöckel, Würzburg

R. Kreienberg, Mainz

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brucker, S.Y., Hartkopf, A.D. & Janni, W. S3-Leitlinie Mammakarzinom: das lokoregionäre Rezidiv. Gynäkologe 51, 556–559 (2018). https://doi.org/10.1007/s00129-018-4277-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00129-018-4277-6

Schlüsselwörter

Keywords

Navigation